GlassScriptPhysician profile
Victor Lara
NPI 1306215918
$4,734.55
in general payments reported to CMS, 2019-2025
26 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.23 · 2022: $592 · 2023: $1,287 · 2024: $1,545 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,103 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,102.68 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $736.23 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $710.57 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $655.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $423.07 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $317.69 | 2022-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $236.38 | 2022-2025 | Verquvo, Belsomra, Capvaxive |
| Exact Sciences Corporation | $192.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $185.53 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $156.11 | 2023-2024 | Xarelto |
| Dexcom, INC. | $154.43 | 2022-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $146.74 | 2023-2025 | Rexulti, Nuedexta |
| Amgen INC. | $144.45 | 2022-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.86 | 2022-2025 | Jardiance, Tradjenta |
| Lundbeck LLC | $116.19 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $94.69 | 2024 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $66.77 | 2023-2025 | |
| Sanofi Pasteur INC. | $59.86 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.36 | 2022-2024 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $41.27 | 2024-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $27.11 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.42 | 2022 | |
| Nevro Corp. | $19.23 | 2023 | Senza |
| Xeris Pharmaceuticals, INC. | $18.42 | 2025 | Gvoke Hypopen |
| Abbvie INC. | $16.45 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.43 | 2022 | |
| Pfizer INC. | $15.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Lara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.